Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage III bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 31 for your search:
Start Over
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-045, NCI-2014-02598, 152903, 2014-002009-40, NCT02256436
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29294, NCI-2015-00200, 2014-003231-19, NCT02302807
Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-75, NCI-2009-00170, CDR0000492014, 7435, CCC-PHII-75, NCI-7435, NCT00365157
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
Everolimus With or Without Paclitaxel as First-Line Therapy in Treating Patients Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-147, NCI-2013-00308, 1008-13, 1011004329, NCT01215136
Gemcitabine Hydrochloride and Cisplatin in Treating Patients With High-Grade Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Biological Therapy in Improving Immune Reconstitution after Chemotherapy in Older Patients with Stage I-III Breast, Stage II Bladder, or Stage II-III Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 11-C-0146, NCI-2013-01487, 110146, P09590, NCT01339000
Dose Dense Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-071, NCI-2012-00649, NCT01589094
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU12-160, NCI-2013-00935, NCT01780545
3D Conformal Radiation Therapy after Surgery in Treating Patients with High-Risk Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RAD2271-12, NCI-2013-01381, NCT01954173
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients with Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHII-130, NCI-2014-01294, P9653_A02PAMDREVW01, 9653, NCT02178241
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0103-018, NCI-2014-02470, NCT02236195
Surgery with or without Postoperative Intensity Modulated Radiation Therapy in Treating Patients with Urothelial Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GU001, NCI-2014-02061, NCT02316548
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-052, NCI-2015-00614, 2014-002206-20, NCT02335424
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-275, NCI-2015-00650, NCT02387996
A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Image-Guided Radiation Therapy and Gemcitabine Hydrochloride in Treating Patients with Stage II-III Bladder Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-031, NCI-2010-01234, NCT01104350
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11105, NCI-2012-01040, CDR0000737061, NCI-2013-01545, P9008_A10PAMDREVW01, 9008, NCT01638533
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Start Over